Challenges and new discoveries in the treatment of leishmaniasis

Singh, Sarman; Sivakumar, R

doi:10.1007/s10156-004-0348-9

Cited by 240 publications

(208 citation statements)

References 57 publications

(117 reference statements)

Supporting

Mentioning

189

Contrasting

Unclassified

Order By: Relevance

“…More recently, miltefosine (hexadecylphosphocholine) has demonstrated efficacy against visceral leishmaniasis when administered orally (Sundar et al, 2000). However, current treatment strategies all suffer from drawbacks which include toxicity, developing resistance, administration by injection, and expense (Ouellette et al, 2004;Singh and Sivakumar, 2004).…”

Section: Introductionmentioning

confidence: 99%

Leishmania tarentolae: Purification and characterization of tubulin and its suitability for antileishmanial drug screening

Yakovich

Ragone

Alfonzo

et al. 2006

Experimental Parasitology

View full text Add to dashboard Cite

Previously, tubulin has been purified from Leishmania amazonensis and used to identify novel molecules with selective antimitotic activity. However, Leishmania amazonensis is pathogenic and requires a relatively expensive medium for large-scale cultivation. Herein, the purification and characterization of tubulin from the non-pathogenic Leishmania tarentolae is reported, together with the sequence of α-and β-tubulin from this organism. This protein was purified by sonication, diethylaminoethyl-Sepharose chromatography, and one assembly-disassembly cycle in 1% overall recovery based on total cellular protein. L. tarentolae tubulin was indistinguishable from the corresponding L. amazonensis protein in terms of binding affinity for dinitroaniline sulfanilamides and sensitivity to assembly inhibition by these compounds. The amino acid sequences derived from the L. tarentolae α-and β-tubulin genes were 99.6% and 99.4% identical to the corresponding amino acid sequences from the L. major Friedlin strain. These results indicate that tubulin from L. tarentolae is suitable for use in drug screening.

show abstract

Section: Introductionmentioning

confidence: 99%

Leishmania tarentolae: Purification and characterization of tubulin and its suitability for antileishmanial drug screening

Yakovich

Ragone

Alfonzo

et al. 2006

Experimental Parasitology

View full text Add to dashboard Cite

show abstract

“…Injections with SSG are very painful and serious adverse events including death from sudden cardiac arrest have been observed. 26,27 Thakur et al 27 in their observational study with 80 VL patients with SSG treatment observed different types (abnormal P, R, T waves; elevation/depression of ST segment; and prolonged QT interval) of cardiac toxicity in 6%-40% of cases and death due to cardiac toxicity among 5%. Other minor side effects included loss of appetite, metallic taste in mouth, and arthralgia.…”

Section: Treatmentmentioning

confidence: 99%

Challenges for management of post kala-azar dermal leishmaniasis and future directions

Mondal¹,

Hamano²,

Hasnain³

et al. 2014

RRTM

View full text Add to dashboard Cite

Post kala-azar dermal leishmaniasis (PKDL) is a skin complication resulting from infection with Leishmania donovani (LD) parasite. It mostly affects individuals who have previously suffered from visceral leishmaniasis (VL) caused by LD. In some cases, PKDL develops among people infected with LD, but do not show any symptoms of VL. Clinical presentation includes hypopigmented macules/papules/nodules or polymorphic lesions (combination of two or more lesions). Except for skin lesions, PKDL patients are generally healthy and usually do not seek medical care. These patients play an important role in interepidemic transmission of the infection and subsequent VL outbreak. Therefore, proper diagnosis and treatment of PKDL patients is important for the control of VL in endemic countries, especially in the Indian subcontinent where VL is anthroponotic. Here, we report the challenges in the estimation of PKDL burden, its diagnosis, and treatment, and suggest possible solutions based on recent literature, reports, published manuals, and web-based information.

show abstract

“…Although analogs of lipophospholipids (LPAs) were developed as anticancer agents, these compounds also have strong antiparasitic activity in vitro (Singh and Sivakumarm 2004). Due to its chemical nature as a lecithin analog, LPAs interact with a variety of sub cellular structures and biochemical pathways.…”

Section: Miltefosinementioning

confidence: 99%

Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs

2011

View full text Add to dashboard Cite

Current drugs for the treatment of visceral leishmaniasis are inadequate. No novel compound is in the pipeline. Since economic returns on developing a new drug for neglected disease, leishmaniasis is so low that therapeutic switching represents the only realistic strategy. It refers to ''alternative drug use'' discoveries which differ from the original intent of the drug. Amphotericin B, paromomycin, miltefosine and many other drugs are very successful examples of ''new drugs from old''. This article reviews the discovery, growth and current status of these drugs and concluded that the potential of this approach (therapeutic switching) may use in the development of new antileishmanials in future also.

show abstract

Challenges and new discoveries in the treatment of leishmaniasis

Cited by 240 publications

References 57 publications

Leishmania tarentolae: Purification and characterization of tubulin and its suitability for antileishmanial drug screening

Leishmania tarentolae: Purification and characterization of tubulin and its suitability for antileishmanial drug screening

Challenges for management of post kala-azar dermal leishmaniasis and future directions

Therapeutic switching in leishmania chemotherapy: a distinct approach towards unsatisfied treatment needs

Contact Info

Product

Resources

About